Summary
Amgen Inc. (AMGN) announced on April 2, 2012, a significant collaboration agreement with AstraZeneca plc concerning five of Amgen's proprietary clinical-stage inflammation programs: AMG 139, AMG 157, AMG 181, AMG 557, and brodalumab. This partnership aims to jointly develop, manufacture, and commercialize these products globally, excluding certain pre-existing territories for brodalumab and AMG 557. The deal involves an upfront payment from AstraZeneca and a shared approach to costs and profits, with AstraZeneca initially funding a larger portion of expenses through 2014. This collaboration represents a strategic move for Amgen to advance its pipeline while sharing development risks and costs. Investors should note the financial implications, including the upfront payment and the profit-sharing model, as well as the specific responsibilities for development and commercialization leadership for each product. The agreement includes an exclusivity clause to prevent competitive product development, underscoring the commitment to the partnered programs and a structure designed to continue in perpetuity unless specific termination conditions are met.
Key Highlights
- 1Amgen entered into a Collaboration Agreement with AstraZeneca on April 2, 2012, focused on five inflammation programs.
- 2The collaboration covers the global development, manufacturing, and commercialization of AMG 139, AMG 157, AMG 181, AMG 557, and brodalumab.
- 3AstraZeneca made an upfront payment of $50 million to Amgen.
- 4AstraZeneca will initially fund approximately 65% of costs for the 2012-2014 period, with costs and global profits shared thereafter.
- 5Amgen will retain low single-digit royalties for brodalumab and mid single-digit royalties for other products, with subsequent equal profit sharing.
- 6Each company will lead development and commercial strategy for specific products within the collaboration, overseen by joint governing bodies.
- 7The agreement includes an exclusivity commitment preventing the development of 'distracting products' that target the same molecules.